Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

for the first quarter of 2010. The decline for SG&A results from lower compensation and market research expenses during the quarter.  
  • Cash and cash equivalents were $73.8 million as of March 31, 2011, compared with $83.3 million as of December 31, 2010 and $55.2 million as of March 31, 2010. Net cash burn for the first quarter of 2011 was approximately $9.4 million.
  • For 2011, management anticipates total operating expenses will be slightly higher than those reported for 2010, which were approximately $68 million. The increase for operating expense is expected to arise from costs associated with additional activities related to clinical trials and manufacturing. The company continues to expect net cash burn of $47 to $52 million for the year 2011.

  • Upcoming Corporate and Scientific PresentationsHalozyme representatives are scheduled to present at the following events:

  • Bank of America Merrill Lynch Health Care Conference in Las Vegas, May 12, 2011 at 11:10 a.m. PDT (2:10 p.m. EDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. The replay will be available for six months after the event.
  • American Diabetes Association Scientific Sessions – June 24-28, 2011 in San Diego. Halozyme has been notified of acceptance for two presentations of results and data from its Ultrafast Insulin program.

  • Conference CallHalozyme management will host a conference call and webcast on May 6, 2011 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
    (Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
    (Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
    (Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
    Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
    ... 13 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that Evan M. Levine,ADVENTRX,s chief executive officer, ... Fifth Annual Growth Conference on Wednesday,September 19th, ...
    ... ... to inhibit ... 13, 9:45 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Sept. 13 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ...
    ... VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... today that it received a,favourable decision from ... an attempt by Johnson & Johnson,s subsidiary, ... Zealand Patent 523799, which,pertains to compositions comprising ...
    Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4
    (Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
    (Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
    (Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
    Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
    ... The changes to the publication requirements of new ... XVIII International Botanical Congress in Melbourne in July 2011 ... To address practical questions arising from the Congress decisions, the ... a series of seven exemplar papers, one each day for ...
    ... the Greek word for "glue," hold the brain,s neurons together ... but scientists have long puzzled over their prominence in the ... Tel Aviv University researchers say that glia cells are central ... and stores information. According to Ph.D. student Maurizio ...
    ... the Gobi desert are usually long and very cold ... of livestock died in Mongolia and the re-introduced wild ... Walzer from the University of Veterinary Medicine, Vienna have ... GPS telemetry to provide insights into the effect of ...
    Cached Biology News:Brave new world 2Brave new world 3Brain's connective cells are much more than glue 2Brain's connective cells are much more than glue 3Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 2Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 3
    Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
    Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
    Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
    Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
    Biology Products: